NRC-2694

Research use only, not for human use.

NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.

NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.(In Vitro):NRC-2694 (80 ng) induce comparable inhibition of EGFR expression.(In Vivo):NRC-2694 (10 mg/kg) regresses the tumor in mice. The maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (p.o.), in toxicity studies .

NRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression.

In toxicity studies, the maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (po). NRC-2694 (10 mg/kg) regresses the tumor in mice.

——

Angiogenesis

EGFR

Influenza virus

——

——

936446-61-6

418.497

C24H26N4O3

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (597.39 mM)

COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCN1CCOCC1

——

(-20℃)

With Ice Pack

≥ 2 years